Loading...
Two major trials of indinavir in combination with two nucleside analogues convincingly demonstrate the greater efficacy of the three-drug regimen.
The protease inhibitor indinavir became available in early 1996 largely based on the results of antiviral data from trials that had not been published, and the major clinical trial demonstrating clinical efficacy had not been completed. Two of the major studies using this agent are published here.
In study 035, sponsored by Merck, the manufacturer of indinavir, patients were eligible for partipation if they had received AZT for at least 6 months and had CD4 cell counts between 50 and 400 and viral loads of at least 20,000 copies/ml. Furthermore, they were excluded if they had prior antiretroviral t…